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ABSTRACT 
Background: Nimesulide is a nonsteroidal, anti-inflammatory drug that has 
been used for a wide range of acute and chronic pain. A once-daily formulation 
of nimesulide is now commercially available, but its effectiveness in pain man- 
agement after dental surgery has not been assessed. 
Objective: The aim of this study was to assess the analgesic effectiveness 
and tolerability of oral treatment with once-daily nimesulide versus ibuprofen 
q6h over 24 hours in patients with postoperative pain associated with surgical 
extraction of an impacted third molar. 
Methods: This 24-hour, double-blind, randomized, ouble-dummy, parallel- 
group study was conducted at a private practice in Caracas, Venezuela. Patients 
aged between 12 and 60 years with moderate to severe pain after extraction of 
an impacted third molar were enrolled. Patients were randomized to receive a 
single dose of nimesulide (300-mg tablet) or ibuprofen (400-mg tablets) q6h for 
24 hours. For double-dummy design, patients in the nimesulide group also 
received ibuprofen placebo tablets, to be taken q6h for 24 hours, and patients 
in the ibuprofen group received a nimesulide placebo tablet. The primary end 
points were pain intensity (PI) and pain relief scores over 24 hours. Secondary 
end points included total pain relief, PI difference (PID), sum of PID (SPID), time 
to first measurable change in PI 0e, PID ~10 mm), and use of rescue medication 
(acetaminophen). Patients also rated the treatment's effectiveness a very poor 
to very good on questioning by the study investigator. Spontaneously reported 
adverse ffects (AEs) were recorded. 
Results: Eighty-six patients were enrolled (56 females, 30 males), with 43 pa- 
tients per treatment group (mean age: nimesulide group, 25.2 years; ibuprofen 
group, 24.2 years). The baseline characteristics were statistically similar between 
the 2 groups. Compared with baseline, mean PI scores were significantly ower in 
both treatment groups at all time points throughout the study (P < 0.001). Mean 
Accepted for publication March 18, 2005. 
Reproduction in whole or part is not permitted. 
doi:l 0.1016/j.curtheres.2005.06.007 
0011-393X/05/$19.00 
172 Copyright © 2005 Excerpta Medica, Inc. 
M. Bocanegra et al. 
PI scores were significantly lower in the nimesulide group compared with the 
ibuprofen group at 15 and 45 minutes and 1 hour after study drug administra- 
tion (P _< 0.049). Time to first measurable change in PI was within the first 
15 minutes in 22 patients (52%) in the nimesulide group and in 14 patients 
(33%) in the ibuprofen group (P = 0.03). Analgesia lasted 24 hours with nime- 
sulide and ibuprofen (PI scores at 24 hours, 9.4 and 3.6, respectively). The 
mean PR score was significantly lower in the uimesulide group compared with 
the ibuprofen group at 1 hour after study drug administration (P = 0.049). 
Compared with baseline, PID and SPID were significantly higher in both treat- 
ment groups throughout the study (P < 0.001). Significantly more patients in 
the nimesulide group than in the ibuprofen group reported that treatment pro- 
vided effective pain relief (82% vs 73%; P = 0.013). No AEs were reported in 
either treatment group throughout he study. Use of rescue medication was 
statistically similar between the nimesulide and ibuprofen groups (38% and 
31%, respectively). 
Conclusions: In this study of patients with moderate to severe pain after 
extraction of impacted third molars, nimesulide and ibuprofen provided effec- 
tive 24-hour relief. However, the results suggest hat the analgesic effect of 
nimesulide had a faster onset (<15 minutes) and was stronger (based on patient 
opinion) than that of ibuprofen. Both study drugs were well tolerated. (Curr 
Ther Res Clin Exp. 2005;66:172-180) Copyright © 2005 Excerpta Medica, Inc. 
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INTRODUCTION 
The pain that follows the extraction of an impacted third molar is an acute, 
short-lasting (2 hours to 3 days) pain that reaches its maximum intensity during 
the early (first 4 hours) postextraction period. This type of pain is widely used 
to evaluate the effectiveness of analgesic agents, especially in single doses. 1-4 
Oral nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in relieving 
mild or moderate pain, and they are more likely to be used in ambulatory 
patients compared with their injectable counterparts. The analgesic action of 
nimesulide has been documented in a wide range of acute and chronic pain. >4 
Nimesulide is an NSAID with pharmacodynamic properties that differ from 
those of other compounds in the same class. In addition to inhibiting the pain 
receptors associated with the generation of prostaglandins, nimesulide inhibits 
the release of oxidizers from activated neutrophils. This drug also has a scav- 
enger effect on hypochloric acid, which, combined with the proteolytic enzymes 
produced by these neutrophils during the inflammatory process, result in tox- 
icity in tissues. 5,6 
Nimesulide decreases histamine release by mastoid ceils and inhibits the 
production of platelet-activating factor in basophils. The cyclooxygenase 
(COX)-I/COX-2 ratio of nimesulide results in excellent olerability, including a 
low incidence (9%) of gastrointestinal dverse ffects (AEs). 7 
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An oral formulation (300-mg tablet) of controlled-release nimesulide* devel- 
oped in 2003 allows for once-daily dosing. A 100-mg dose is released immediate- 
ly after administration to allow pain relief within 1 hour, and a 200-mg dose is 
released over the subsequent 24 hours for a lasting analgesic effect. With the 
first dose, Tma x is -<4 hours. With repeated osing, Tma x is -<2 hours, and a ther- 
apeutic oncentration is maintained for 24 hours. 
Ibuprofen, the first NSAID derived from propionic acid, is used for mild or 
moderate pain (eg, in dysmenorrhea) t dosages of 200 to 400 mg q4-6h. It is 
absorbed quickly after administration. Tma x is 1 to 2 hours, and tl/2 is -2 hours. 
Ibuprofen is cleared rapidly and completely, with 90% of the dose being excret- 
ed in the urine as metabolites or their conjugates. However, in 5% to 15% of 
cases, ibuprofen is associated with gastrointestinal AEs, including epigastric 
pain, nausea, and fullness. To minimize the risk for these AEs, ibuprofen should 
be given with food. Thrombocytopenia, cutaneous eruptions, visual disturbance, 
fluid retention, and edema occur less frequently. 4 
The aim of the present study was to assess the onset of the analgesic effect 
and the effectiveness and tolerability of oral treatment with a single dose of 
nimesulide 300 mg versus ibuprofen 400 mg q6h over 24 hours in patients with 
moderate or severe pain after surgical extraction of an impacted third molar. 
PATIENTS AND METHODS 
This 24-hour, double-blind, randomized, ouble-dummy, parallel-group study was 
conducted at a private practice in Caracas, Venezuela. After surgery but before 
administration of the study drugs, patients were assigned, using a computer- 
generated table of random numbers, to 1 of 2 treatment groups: a single dose of 
nimesulide (300-mg tablet) or ibuprofenl (400-mg tablets) q6h for 24 hours. For 
double-dummy design, patients in the nimesulide group also received ibuprofen 
placebo tablets, to be taken q6h for 24 hours, and patients in the ibuprofen group 
received animesulide placebo tablet. The patients were evaluated over a 24-hour 
period at 5, 10, 15, 30, and 45 minutes and 1, 6, 12, and 24 hours after surgery. 
A variety of measures were used to determine the effectiveness of the treat- 
ments. Pain intensity (PI) was rated on a 100-mm visual analog scale (VAS) (0 = 
no pain to 100 -- worst pain imaginable), and pain relief (PR) was rated on a 
5-point scale (0 = no relief; 1 = little relief; 2 = some relief; 3 = much relief; and 
4 = complete relief). Total PR (TOPAR) was calculated as the sum of the PR 
scores at 15, 30, and 45 minutes and 1, 6, 12, and 24 hours (Z[PR × h]l ~n)" The 
PI difference (PID) and the sum of the PIDs (SPID) (Z[PI n - PI,_ 111 - ,)  were also 
calculated. Time to PID ___10 mm was considered the first measurable change in 
PI (ie, the onset of analgesic effect). Use of rescue medication (acetaminophen 
500-mg tablet or corticosteroids) was recorded. Patients also rated the effective- 
ness of the treatment in response to the following multiple-choice question 
*Trademark: Normodual ® (Biocontrolled Laboratories, Caracas, Venezuela). 
tTrademark: Brugesic ® (Labratorios Elmor, Caracas, Venezuela). 
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posed by the investigator: "In your opinion, did the medication relieve your 
pain very poorly, poorly, moderately, well, or very well?" 
Healthy female and male patients between 12 and 60 years of age who had 
undergone surgical extraction of impacted third molars, had moderate to 
severe postoperative pain (PI score, 40-80), and were able to understand the 
procedures they were to follow were eligible for the study. 
All patients provided written informed consent o participate in this trial. 
Consent for patients aged <18 years was also provided by their legal represen- 
tatives. The study protocol was approved by an independent ethics committee. 
Extraction of a third molar was performed with patients under local or gener- 
al anesthesia, using a standard technique. The operative time (from the first inci- 
sion to the end of suturing) was recorded by the investigator for each patient. 
Use of short-acting analgesics was prohibited for 6 hours before surgery, and 
use of long-acting analgesics was prohibited for 24 hours before surgery. 
Patients with a known sensitivity to NSAIDs, any cardiac condition, renal or 
hepatic dysfunction, history of or an existing gastrointestinal condition, drug 
dependency, alcohol abuse, hypertension, uncontrolled iabetes meUitus, or 
hematologic dysfunction or coagulopathy were excluded from the study. 
Pregnant or breast-feeding women were also excluded. 
AEs reported spontaneously by patients during the 24-hour study period 
were recorded by the investigator. 
Use of NSAIDs other than the study drugs was prohibited. Acetaminophen 
(500-mg tablet) was allowed as rescue medication. The patient could use acet- 
aminophen as early as 30 minutes after study drug administration, provided 
that the acetaminophen use was carefully recorded. Corticosteroids were al- 
lowed for use as anti-inflammatory medication as early as 1 hour after study 
drug administration, provided that the intake time, dose, and route of admin- 
istration were recorded by the investigator. 
Statistical Analysis 
Analysis of variance was carried out for age, body weight, height, systolic 
and diastolic blood pressure (SBP/DBP), and PI scores. PID, SPID, PR, and 
TOPAR were analyzed using the Wilcoxon range test (intragroup) and the Mann- 
Whitney U test (intergroup). The numbers of patients who used rescue medica- 
tion and patients' opinions of the drugs' effectiveness were evaluated using the 
Fisher exact test at ~ = 0.05 and 13 = 0.1. This study was calculated to have >95% 
power to detect differences in PI score of 10% between treatments, and a 5% ¢~ 
error. P < 0.05 was considered statistically significant. SPSS version 7.5 (SPSS 
Inc., Chicago, Illinois) was used for the statistical calculations. 
RESULTS 
The study included 86 patients (56 females, 30 males) divided into 2 groups 
of 43 patients each (mean age: nimesulide group, 25.2 years; ibuprofen group, 
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24.2 years). The baseline demographic and clinical characteristics were sta- 
tistically similar between the 2 groups (Table I). The 2 groups were also sta- 
tistically similar in terms of indications for surgery. 
The most common diagnoses in both groups were inadequate jawbone space 
(nimesulide group, 25 patients [58%]; ibuprofen group, 22 patients [51%]), improp- 
er angulation of the tooth (11 [26%] and 13 [30%] patients, respectively), and the 
need for space for orthodontia (7 [16%] and 8 [19%] patients, respectively). 
The pain began during the first 2 hours after the removal of the impacted 
third molar in 18 patients (42%) receiving ibuprofen and in 22 (51%) receiving 
nimesulide. Pain started 2 to 4 hours after extraction in 20 (47%) and 14 (33%) 
patients in the nimesulide and ibuprofen groups, respectively. Seven patients 
(16%) in the nimesulide group experienced pain <1 hour after the intervention 
compared with 3 patients (7%) in the ibuprofen group. None of these differ- 
ences were statistically significant. 
In both groups, the mean PI score was significantly lower at all time points 
compared with baseline (all, P < 0.001). At 15 and 45 minutes and 1 hour, the 
mean (SD) PI scores were significantly lower in the nimesulide group compared 
with the ibuprofen group (15 minutes: 37.3 [19.2] vs 44.6 [18.6]; P--  0.047; 
45 minutes: 18.2 [20.0] vs 28.1 [22.6]; P = 0.033; and 1 hour: 13.1 [19.2] vs 20.8 
[19.6]; P-- 0.049); at all subsequent time points, the scores were statistically 
similar between the 2 groups (Table II). 
The first significant change of 510 mm on the VAS (ie, onset of action) was 
observed in the first 15 minutes by 22 patients (51%) in the nimesulide group 
compared with 14 (33%) in the ibuprofen group (P = 0.03) (Table III). 
Table I. Baseline demographic and clinical characteristics of the study patients (N -- 86). 
Nimesulide Ibuprofen 
Characteristic (n = 43) (n -- 43) P 
Age, y 0.61 
Mean 24.2 25.2 
Range 14-52 15-25 
Sex, no. (%) 1.0 
Female 28 (65) 28 (65) 
Male 15 (35) 15 (35) 
Body weight, 
mean (SD), kg 64.6 (18.6) 63.4 (15.6) 0.75 
Height, mean (SD), cm 1.7 (0.1) 1.7 (0.1) 0.73 
Blood pressure, 
mean (SD), mm Hg 
Systolic 11 3.0 (7.5) 112.0 (7.4) 0.60 
Diastolic 69.1 (8.7) 66.4 (8.0) 0.16 
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Table III. Measures of pain intensity and changes in pain after administration of single- 
dose nimesulide 300 mg (n = 43) or ibuprofen 400 mg q6h for  24 hours 
(n = 43) for  postoperative analgesia in patients undergoing dental surgery.* 
Scale 15Min  30Min  45Min  1 H _>6H 12H 24H 
First significant change PID 
(_>10 mm) 
Nimesulide, no. (%) 22 (51) 10 (23) 4 (9) 4 (9) 3 (7) - - 
Ibuprofen, no. (%) 14 (33) 15 (35) 6 (14) 4 (9) 4 (9) - - 
Pf 0.03 . . . . . .  
PID~ 
Nimesulide 11.1 22.7 30.2 35.3 40.2 43.1 39.0 
Ibuprofen 8.0 16.5 23.4 29.4 40.0 44.9 47.0 
P~ 0.145 0.131 0.094 0.165 0.913 0.772 0.123 
SPID 
Nimesulide 11.8 33.7 63.9 99.2 139.4 182.4 221.4 
Ibuprofen 8.0 24.5 48.0 77.4 116.4 160.2 206.1 
/~ 0.093 0.107 0.064 0.066 0.058 0.084 0.233 
PR scorell 
Nimesulide 1.2 1.9 2.6 3.0 3.5 3.6 3.5 
Ibuprofen 0.9 1.7 2.4 2.5 3.2 3.5 3.6 
/~ 0.146 0.551 0.280 0.049 0.097 0.658 0.321 
TOPAR 
Nimesulide 1.2 3.2 5.1 8.7 12.1 15.8 19.1 
Ibuprofen 0.9 2.6 5.0 7.4 12.7 14.0 17.6 
P~ 0.146 0.294 0.308 0.160 0.965 0.067 0.136 
PID -- pain intensity difference; SPID = sum of PID; PR = pain relief; TOPAR = total PR. 
*P < 0.001 versus baseline for all scores in both treatment groups. 
tWilcoxon range test. 
~As measured on a 100-mm visual analog scale: 0 = no pain to 100 = worst pain imaginable. 
§Mann-Whitney U test. 
IIScale: 0 = no relief; 1 = little relief; 2 = some relief; 3 -- much relief; and 4 = complete relief. 
Analgesia lasted 24 hours in both groups, as indicated by the mean PI scores 
(9.4 and 3.6 in the nimesulide and ibuprofen groups, respectively). 
In both groups, the mean PID and the SPID values were significantly higher at 
all time points compared with baseline (all, P < 0.001); PID and SPID were statis- 
tically similar between the 2 groups at all time points (Table Ill). 
In both groups, the mean PR and TOPAR scores were significantly higher at 
all t ime points compared with baseline (all, P < 0.001) (Table Ill). At 1 hour, the 
mean PR score was significantly higher in the nimesulide group compared with 
the ibuprofen group (3.0 vs 2.5; P = 0.049). 
Rescue medication use was statistically similar between the nimesulide and 
ibuprofen groups (16 [38%] vs 13 [31%] patients, respectively). Most patients 
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needing rescue medication in the nimesulide group needed it between 2 and 
4 hours after study drug administration; in the ibuprofen group, rescue medica- 
tion was given most often between 4 and 6 hours after study drug administra- 
tion. Twenty-seven (63%) and 31 (74%) patients received steroids in the nime- 
sulide and ibuprofen groups, respectively. 
Thirty-five (81%) and 31 (72%) patients receiving nimesulide and ibuprofen, 
respectively, indicated that the analgesic effect of the study drug was good or 
very good (P = 0.013). 
None of the patients reported any AEs during the 24-hour duration of the 
study. 
DISCUSSION 
Several analgesic drugs have been shown to be effective in the treatment of pain 
after the surgical extraction of an impacted third molar. In the double-blind, 
clinical study by Walton et al 8 (200 patients), the NSAIDs ketorolac 30 mg IV and 
diclofenac 75 mg IV, administered with patients under general anesthesia nd 
4 hours after the IV dose, were more effective, as measured on the VAS, com- 
pared with vehicle (P = 0.002) and provided a similar degree of pain relief in 
patients with this type of pain. 
In a randomized, active-controlled, parallel-group study in 128 patients, Jung 
et al 9 found that the combinations of tramadol-acetaminophen 75/650 mg and 
codeine-acetaminophen-ibuprofen 20/500/400 mg in single doses were compa- 
rable in the onset of analgesia nd analgesic efficacy, as measured on the VAS, 
in acute postoperative dental pain. 
In other studies, a single dose of valdecoxib 40 mg compared with a single 
dose of rofecoxib 50 mg administered postoperatively provided a similar mag- 
nitude of analgesic effect, as measured by line-weighted TOPAR at 6 hours after 
dosing.10,11 
In a randomized, double-blind study, Zelenkas et al 4 compared the efficacy 
of single-dose lumiracoxib 100 to 400 mg, ibuprofen 400 mg, and placebo over 
12 hours in 202 patients with postoperative dental pain. The primary efficacy 
end point was PID, which was significantly different in the 2 groups receiving 
active drugs compared with the placebo group from 1 to 12 hours after dosing. 
In a single-dose, randomized, active-controlled, parallel-group trial in 130 pa- 
tients undergoing surgical extraction of a third molar, Bracco et a112 found that 
rofecoxib 50 mg/d and nimesulide 200 mg/d, given for 6 days after surgery, pro- 
vided similar effects on clinical signs of local postoperative inflammation. 
Ibuprofen and conventional nimesulide require administration several times 
a day. The once-daily nimesulide formulation used in the present study provid- 
ed analgesia throughout the 24-hour study period. Furthermore, the onset of 
analgesic effect was faster (< 15 minutes) with single-dose nimesulide compared 
with ibuprofen 400 mg q6h. The duration of pain relief (the entire 24-hour obser- 
vation period) was similar with both drugs, as measured using PI and PR scores. 
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CONCLUSIONS 
In this study of 86 patients undergoing surgical extraction of impacted third molars, 
single-dose nimesulide provided analgesia similar to ibuprofen q6h over 24 hours. 
The group receiving nimesulide had a faster analgesic effect (<15 minutes) and a 
better patient rating of effectiveness compared with those receiving ibuprofen. 
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